**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Substance Abuse and Mental Health Services Administration**

**Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies**

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were initially published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently HHS-certified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://www.samhsa.gov/workplace.

**FOR FURTHER INFORMATION CONTACT:**

Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7–1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

**SUPPLEMENTARY INFORMATION:** The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

**HHS-Certified Instrumented Initial Testing Facilities:**

Dynamacare, 6628 50th Street NW., Edmonton, AB Canada T6B 2N7, 780–784–1190 (Formerly: Gamma-Dynacare Medical Laboratories)

Dynamacare*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519–679–1630 (Formerly: Gamma-Dynacare Medical Laboratories)

ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662–236–2609

Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503–486–1023

Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/800–800–2387

Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.)

Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900/800–833–3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center)

LabOne, Inc., d/b/a Quest Diagnostics, 10101 Research Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845 (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for...
Laboratory Services, a Division of LabOne, Inc.)

MedTox Laboratories, Inc., 402 W.,

County Road D, St. Paul, MN 55112,

651–636–7466/800–832–3244

MetroLab-Legacy Laboratory Services,

1225 NE 2nd Ave., Portland, OR

97232, 503–413–5295/800–950–5295

Minneapolis Veterans Affairs Medical

Center, Forensic Toxicology

Laboratory, 1 Veterans Drive,

Minneapolis, MN 55417, 612–725–

2088, Testing for Veterans Affairs

(VA) Employees Only

National Toxicology Laboratories, Inc.,

1100 California Ave., Bakersfield, CA

93304, 661–322–4250/800–350–3515

One Source Toxicology Laboratory, Inc.,

1213 Genoa-Red Bluff, Pasadena, TX

77504, 888–747–3774 (Formerly:

University of Texas Medical Branch,

Clinical Chemistry Division; UTMB

Pathology-Toxicology Laboratory)

Pacific Toxicology Laboratories, 9348

DeSoto Ave., Chatsworth, CA 91311,

800–328–6942 (Formerly: Centinela

Hospital Airport Toxicology

Laboratory)

Pathology Associates Medical

Laboratories, 110 West Cliff Dr.,

Spokane, WA 99204, 509–755–8991/

800–541–7891x7

Phamatech, Inc., 15175 Innovation

Drive, San Diego, CA 92128, 888–

635–5840

Quest Diagnostics Incorporated, 1777

Montreal Circle, Tucker, GA 30084,

800–729–6432 (Formerly: SmithKline

Beecham Clinical Laboratories;

SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated, 400

Egypt Road, Norristown, PA 19403,

610–631–4600/877–642–2216

(Formerly: SmithKline Beecham

Clinical Laboratories; SmithKline Bio-

Science Laboratories)

Quest Diagnostics Incorporated, 8401

Fallbrook Ave., West Hills, CA 91304,

818–737–6370 (Formerly: SmithKline

Beecham Clinical Laboratories)

Redwood Toxicology Laboratory,

3700650 Westwind Blvd., Santa Rosa,

CA 95403, 800–255–2159

Southwest Laboratories, 4625 E. Cotton

Center Boulevard, Suite 177, Phoenix,

AZ 85040, 602–438–8507/800–279–

0027

STERLING Reference Laboratories, 2617

East L Street, Tacoma, Washington

98421, 800–442–0438

US Army Forensic Toxicology Drug

Testing Laboratory, 2490 Wilson St.,

Fort George G. Meade, MD 20755–

5235, 301–677–7085, Testing for

Department of Defense (DoD)

Employees Only

*The Standards Council of Canada

(SCC) voted to end its Laboratory

Accreditation Program for Substance

Abuse (LAPSA) effective May 12, 1998.

Laboratories certified through that

program were accredited to conduct

forensic urine drug testing as required

by U.S. Department of Transportation

(DOT) regulations. As of that date, the

certification of those accredited

Canadian laboratories will continue

under DOT authority. The responsibility

for conducting quarterly performance

testing plus periodic on-site inspections

of those LAPSA-accredited laboratories

was transferred to the U.S. HHS, with

the HHS’ NLCP contractor continuing to

have an active role in the performance

testing and laboratory inspection

processes. Other Canadian laboratories

wishing to be considered for the NLCP

may apply directly to the NLCP

contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to

be qualified, HHS will recommend that

DOT certify the laboratory (Federal

Register, July 16, 1996) as meeting the

minimum standards of the Mandatory

Guidelines published in the Federal

Register on April 30, 2010 (75 FR

22809). After receiving DOT

certification, the laboratory will be

included in the monthly list of HHS-
certified laboratories and participate in

the NLCP certification maintenance

program.

Summer King,

Statistician.

[FR Doc. 2015–33222 Filed 1–5–16; 8:45 am]

BILLING CODE 4160–20–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Agency Information Collection

Activities: Proposed Collection;

Comment Request

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: In compliance with Section

3506(c)(2)(A) of the Paperwork

Reduction Act of 1995 concerning

opportunity for public comment on

proposed collections of information, the

Substance Abuse and Mental Health

Services Administration (SAMHSA)

will publish periodic summaries of

proposed projects. To request more

information on the proposed projects or

to obtain a copy of the information

collection plans, call the SAMHSA

Reports Clearance Officer at (240) 276–

1243.

Comments are invited on: (a) Whether

the proposed collections of information

are necessary for the proper

performance of the functions of the

agency, including whether the

information shall have practical utility;

(b) the accuracy of the agency’s estimate

of the burden of the proposed collection

of information; (c) ways to enhance the

quality, utility, and clarity of the

information to be collected; and (d)

ways to minimize the burden of the

collection of information on

respondents, including through the use

of automated collection techniques or

other forms of information technology.

Proposed Project: Services Grant

Program for Residential Treatment for

Pregnant and Postpartum Women

(PFW) Quarterly Progress Reports—

NEW

The Substance Abuse and Mental

Health Services Administration (SAMHSA), Center for Substance Abuse

Treatment, has developed a set of

infrastructure development measures in

which recipients of cooperative

agreements will report on various

benchmarks on a quarterly-annual basis.

The infrastructure development

measures are designed to collect

information at the grantees-level and

program-level.

The draft infrastructure measures are

based on the programmatic

requirements conveyed in TI–14–005,

Services Grant Program for Residential

Treatment for Pregnant and Postpartum

Women.

The purpose of this program is to

provide funding to improve treatment

for low-income (according to federal

poverty guidelines) women, age 18 and

over, who are pregnant, postpartum (the

period after childbirth up to 12 months),

and their minor children, age 17 and

under, who have limited access to

quality health services.

The pregnant and postpartum women

program will implement parenting and

treatment evidence-based practice

models and a feedback loop developed
to enable the grantee and the programs
to identify barriers and test solutions

through direct services. The expected

outcomes of these grants will include
decreases in the use and/or abuse of

prescription drugs, alcohol, tobacco,

illicit and other harmful drugs (e.g.,

inhalants) among pregnant and

postpartum women; increases in safe

and healthy pregnancies; improved

birth outcomes; reduced perinatal and

children; improved mental and

physical health of women and

children; prevention of mental,